论文部分内容阅读
氨甲喋呤为一种治疗儿童肉瘤及血液系统恶性肿瘤的常用化疗药物。此研究的目的在于确定应用氨甲喋呤进行经静脉大剂量、短疗程的骨肉瘤患者氨甲喋呤骨病的发生率及该合并症是否随患者年龄及氨甲喋岭剂量而变化。作者搜集了1977~1994年的87例接受大剂量氨甲喋呤治疗的骨肉瘤患者,男54例,女33例,年龄范围3~28岁(平均12岁)。氨甲喋呤骨病的诊断以特征的X线表现为基础,其中包括
Methotrexate is a commonly used chemotherapeutic agent for the treatment of childhood sarcoma and hematological malignancies. The purpose of this study was to determine the prevalence of methotrexate bone disease in patients treated with methotrexate intravenously in large-volume, short-course osteosarcoma and whether the comorbidity varies with patient age and the amount of carbamazepine. The authors collected 87 cases of osteosarcoma patients treated with high-dose methotrexate from 1977 to 1994, including 54 males and 33 females, ranging in age from 3 to 28 years (mean 12 years old). The diagnosis of methotrexate bone disease is based on characteristic X-ray findings, including